Kurt A Schalper1, Jason Brown2, Daniel Carvajal-Hausdorf2, Joseph McLaughlin2, Vamsidhar Velcheti2, Konstantinos N Syrigos2, Roy S Herbst2, David L Rimm2. 1. Department of Pathology (KAS, JB, DCH, DLR) and Medical Oncology (JM, RSH), Yale University School of Medicine, New Haven, CT; Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH (VV); Oncology Unit, 3rd Department of Medicine, School of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece (KNS). kurt.schalper@yale.edu. 2. Department of Pathology (KAS, JB, DCH, DLR) and Medical Oncology (JM, RSH), Yale University School of Medicine, New Haven, CT; Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH (VV); Oncology Unit, 3rd Department of Medicine, School of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece (KNS).
Abstract
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) are usually measured using subjective methods. Studies suggest that TIL subtypes have independent roles in cancer and that they could support the use of novel immunostimulatory therapies. We simultaneously measured TIL subtypes in non-small cell lung cancer (NSCLC) samples using objective methods and determined their relationship with clinico-pathologic characteristics and survival. METHODS: Using multiplexed quantitative fluorescence (QIF), we measured the levels of CD3, CD8, and CD20 in 552 NSCLC from two independent collections represented in tissue microarrays (YTMA79, n = 202 and YTMA140, n = 350). The level of TILs was obtained in different tumor compartments using cytokeratin stain to define tumor cells and 4',6-Diamidino-2-Phenylindole. Association of TILs with clinical parameters was determined using univariate and multivariable analyses. All statistical tests were two-sided. RESULTS: In both NSCLC collections there was a low correlation between the three TIL markers (linear regression coefficients (R(2)) = 0.19-0.22, P < .001 for YTMA79 and R(2) = 0.23-0.32, P < .001 for YTMA140). No consistent association between the level of TIL subtypes and age, sex, smoking history, tumor size, stage, and histology type was found. In univariate analysis, an elevated CD3 or CD8 signal was statistically significantly associated with longer survival in both collections. However, only CD8 was independent from age, tumor size, histology, and stage in multivariable analysis. High CD20 was associated with longer survival in the YTMA79 cohort. CONCLUSIONS: Increased levels of CD3 and CD8 + TILs are associated with better outcome in NSCLC, but only CD8 is independent from other prognostic variables. Objective measurement of TIL subpopulations could be useful to predict response or evaluate the local immune effect of anticancer immune checkpoint inhibitors.
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) are usually measured using subjective methods. Studies suggest that TIL subtypes have independent roles in cancer and that they could support the use of novel immunostimulatory therapies. We simultaneously measured TIL subtypes in non-small cell lung cancer (NSCLC) samples using objective methods and determined their relationship with clinico-pathologic characteristics and survival. METHODS: Using multiplexed quantitative fluorescence (QIF), we measured the levels of CD3, CD8, and CD20 in 552 NSCLC from two independent collections represented in tissue microarrays (YTMA79, n = 202 and YTMA140, n = 350). The level of TILs was obtained in different tumor compartments using cytokeratin stain to define tumor cells and 4',6-Diamidino-2-Phenylindole. Association of TILs with clinical parameters was determined using univariate and multivariable analyses. All statistical tests were two-sided. RESULTS: In both NSCLC collections there was a low correlation between the three TIL markers (linear regression coefficients (R(2)) = 0.19-0.22, P < .001 for YTMA79 and R(2) = 0.23-0.32, P < .001 for YTMA140). No consistent association between the level of TIL subtypes and age, sex, smoking history, tumor size, stage, and histology type was found. In univariate analysis, an elevated CD3 or CD8 signal was statistically significantly associated with longer survival in both collections. However, only CD8 was independent from age, tumor size, histology, and stage in multivariable analysis. High CD20 was associated with longer survival in the YTMA79 cohort. CONCLUSIONS: Increased levels of CD3 and CD8 + TILs are associated with better outcome in NSCLC, but only CD8 is independent from other prognostic variables. Objective measurement of TIL subpopulations could be useful to predict response or evaluate the local immune effect of anticancer immune checkpoint inhibitors.
Authors: Khalid I Al-Shibli; Tom Donnem; Samer Al-Saad; Magnus Persson; Roy M Bremnes; Lill-Tove Busund Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531
Authors: Valsamo K Anagnostou; Konstantinos N Syrigos; Gerold Bepler; Robert J Homer; David L Rimm Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Omid Hamid; Henrik Schmidt; Aviram Nissan; Laura Ridolfi; Steinar Aamdal; Johan Hansson; Michele Guida; David M Hyams; Henry Gómez; Lars Bastholt; Scott D Chasalow; David Berman Journal: J Transl Med Date: 2011-11-28 Impact factor: 5.531
Authors: K Hiraoka; M Miyamoto; Y Cho; M Suzuoki; T Oshikiri; Y Nakakubo; T Itoh; T Ohbuchi; S Kondo; H Katoh Journal: Br J Cancer Date: 2006-01-30 Impact factor: 7.640
Authors: Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox Journal: Adv Anat Pathol Date: 2017-11 Impact factor: 3.875
Authors: Yuting Liu; Jon Zugazagoitia; Fahad Shabbir Ahmed; Brian S Henick; Scott N Gettinger; Roy S Herbst; Kurt A Schalper; David L Rimm Journal: Clin Cancer Res Date: 2019-10-15 Impact factor: 12.531
Authors: Marta Usó; Eloísa Jantus-Lewintre; Silvia Calabuig-Fariñas; Ana Blasco; Eva García Del Olmo; Ricardo Guijarro; Miguel Martorell; Carlos Camps; Rafael Sirera Journal: Oncoimmunology Date: 2016-12-07 Impact factor: 8.110
Authors: Douglas B Johnson; Jennifer Bordeaux; Ju Young Kim; Christine Vaupel; David L Rimm; Thai H Ho; Richard W Joseph; Adil I Daud; Robert M Conry; Elizabeth M Gaughan; Leonel F Hernandez-Aya; Anastasios Dimou; Pauline Funchain; James Smithy; John S Witte; Svetlana B McKee; Jennifer Ko; John M Wrangle; Bashar Dabbas; Shabnam Tangri; Jelveh Lameh; Jeffrey Hall; Joseph Markowitz; Justin M Balko; Naveen Dakappagari Journal: Clin Cancer Res Date: 2018-07-18 Impact factor: 12.531
Authors: Ila Datar; Miguel F Sanmamed; Jun Wang; Brian S Henick; Jungmin Choi; Ti Badri; Weilai Dong; Nikita Mani; Maria Toki; Luis D Mejías; Maria D Lozano; Jose Luis Perez-Gracia; Vamsidhar Velcheti; Matthew D Hellmann; Justin F Gainor; Kristen McEachern; David Jenkins; Konstantinos Syrigos; Katerina Politi; Scott Gettinger; David L Rimm; Roy S Herbst; Ignacio Melero; Lieping Chen; Kurt A Schalper Journal: Clin Cancer Res Date: 2019-05-03 Impact factor: 12.531